Comparative Pharmacology
Head-to-head clinical analysis: MICONAZOLE NITRATE versus MONISTAT 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICONAZOLE NITRATE versus MONISTAT 7.
MICONAZOLE NITRATE vs MONISTAT 7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal CYP450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Miconazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, reducing ergosterol synthesis and disrupting fungal cell membrane integrity.
Topical: Apply twice daily for 2-4 weeks. Vaginal: 200 mg suppository at bedtime for 3 days, or 100 mg suppository at bedtime for 7 days, or 1200 mg suppository as a single dose. Oral (buccal): 50 mg once daily for 14 days.
Intravaginal administration of 100 mg miconazole nitrate suppository once daily at bedtime for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 20-40 hours) following intravenous administration. This extended half-life supports twice-daily dosing for systemic infections.
Terminal elimination half-life is approximately 24-30 hours following intravaginal administration; clinical significance: supports once-daily dosing.
Miconazole is primarily metabolized in the liver, with less than 1% of an intravenous dose excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 50% of the dose as metabolites. Renal elimination of metabolites is minimal.
Primarily via feces (approximately 87-93% of dose) as unchanged drug and metabolites; renal excretion negligible (<1%).
Category A/B
Category C
Antifungal
Antifungal